Skip to main content
Premium Trial:

Request an Annual Quote

Jonathan Rowe, David Lieberman, David Sidransky, Richard Wender, Richard Lussier, Ignacio Martinez, Duncan Whitney

Jonathan Rowe will take over the role of senior VP of strategy and clinical innovation at Gene Express, the company said last week.
Rowe has worked at Pfizer as a senior director of worldwide pharmaceutical sciences, director of intellectual property strategy management, and clinical director of the cardiovascular risk factors group.
Rowe has also served as a scientific advisor for the law firm Kaye, Scholer, where he was involved in IP litigation for biotechnology and pharmaceutical firms.

GeneNews has appointed three new members to its Colorectal Cancer Clinical Advisory Board: David Lieberman, David Sidransky, and Richard Wender.
Lieberman is a professor of medicine and chief of gastroenterology at Oregon Health Sciences University and the Portland Veterans Affairs Medical Center. In 2007 he received the Laurel for Leadership from the Cancer Research and Prevention Foundation.
Sidransky is a director of the head and neck cancer research program at the Sidney Kimmel Comprehensive Cancer Center, as well as a professor of oncology, cellular and molecular medicine and genetics, and other specialties at the Johns Hopkins University School of Medicine. He received the 2004 Hinda Rosenthal Award from the American Association of Cancer Research.
Wender is chair of the department of family and community medicine at Thomas Jefferson University in Philadelphia and he has served on the steering committee of the National Colorectal Cancer Roundtable and worked with the US Centers for Disease Control and Prevention to develop a training program aimed at colorectal cancer prevention and screening.

Progenika Biopharma announced this week that it has named Richard Lussier as its chief operating officer and general manager; Ignacio Martinez as its chief financial officer; and Duncan Whitney as its chief scientific officer.
Prior to joining Progenika, Lussier spent more than 13 years at Applera, where he held several technical, marketing, and management roles with Applied Biosystems and Celera Genomics. Lussier was most recently at Solexa, which was acquired by Illumina in January 2007.
Martinez joined Progenika in 2005 as the company’s chief financial officer in Spain, and then relocated to Boston as a member of the executive team to set up the company’s US subsidiary. Formerly, Martinez held positions at Seed Capital and Najeti Capital in Spain.
Whitney comes to Progenika from US Genomics, where he was the VP of research and development.

Filed under

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.